Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 117

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 117
---
” or “we”) operations; business strategies; future cash flows; financing plans; plans and objectives
of management; any other statements regarding future operations, future cash needs, business plans and future financial results,
and any other statements that are not historical facts.

From
time to time, forward-looking statements also are included in our other periodic reports on Form 10-K, 10-Q and 8-K, in our press
releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking
statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance
and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions
and beliefs about future events and are subject to risks, uncertainties and other factors, including risks related to market,
economic and other conditions; our current liquidity position, the need to obtain additional financing to support ongoing operations,
Pelthos’s ability to continue as a going concern; Pelthos’s ability to maintain the listing of its Common
Stock on the NYSE American LLC, Pelthos’s ability to manage costs and execute on its operational and budget
plans; and, Pelthos’s ability to achieve its financial goals. Many of those factors are outside of our control and could
cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light
of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might
occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements
concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified
in their entirety by the cautionary statements contained or referred to in this Report.

Except
to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result
of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or
otherwise.

Overview

Prior
to the Merger outlined above, we operated as a clinical-stage biotech company focused on developing and commercializing new therapeutics
to alleviate pain. Following the Merger, we are focused, though not necessarily